AXLRx Merck intelligence — Oncology: 3 reports covering Oncology.
Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry.
How the US NSCLC population segments by histology and biomarker, where it is actually diagnosed and tested, and where the gap between diagnosis and treatment costs patients.
CMS routes all four approved 1L NSCLC IO agents through Part B buy-and-bill at ASP+6%, but PD-L1 assay requirements split coverage into three distinct biomarker-testing tiers.